Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis (The Manila Times) - Mar 31, 2026 - "The EMA's PRIME designation is supported by compelling visual-function results from the Phase 2 ACUITY trial in ON...Following a successful meeting with the FDA in the fall of 2025, Oculis is now advancing the PIONEER program, which includes three global registrational trials in ON and a second rare neuro-ophthalmic disease, non-arteritic anterior ischemic optic neuropathy (NAION). The first registrational trial in the program, PIONEER-1 in ON, was initiated in Q4 2025, with clinical site activation progressing as planned."
European regulatory • Trial status • Optic Neuritis
|